Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

The death comes as multiple infectious diseases are surging throughout the US, including the 10th wave of the COVID-19 ...

Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it.

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

Queenslanders have been urged to overcome ‘vaccine fatigue’ and take up an offer of free vaccinations amid predictions of a ...

The Illinois Department of Public Health (IDPH) announced that the state’s overall respiratory illness level has moved up from Low to Moderate, meaning that Illinoisans face an increased chance of ...

Today has seen a lot of movement in Russia's Kursk region, where Ukraine launched an offensive last year. We'll be back tomorrow with more updates on the war in Ukraine. But here is a look at the ...

The U.S. Congress formally certified Republican President-elect Donald Trump's November election victory over Democratic Vice President Kamala Harris, clearing the way for him to be sworn in on ...